Structural biology in drug design: selective protein kinase inhibitors.
about
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252aFinding a better path to drug selectivityCrystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitorCellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].X-ray structures of checkpoint kinase 2 in complex with inhibitors that target its gatekeeper-dependent hydrophobic pocketStructural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapyCompleting the structural family portrait of the human EphB tyrosine kinase domainsThe ATPases: a new family for a family-based drug design approach.Femtosecond crystallography of membrane proteins in the lipidic cubic phase.The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancerStructure determination of glycogen synthase kinase-3 from Leishmania major and comparative inhibitor structure-activity relationships with Trypanosoma brucei GSK-3.ATPases as drug targets: learning from their structure.Revealing the favorable dissociation pathway of type II kinase inhibitors via enhanced sampling simulations and two-end-state calculations.Chemical genomics as an emerging paradigm for postgenomic drug discovery.Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and Type 2 diabetes treatment.Protein kinase-inhibitor database: structural variability of and inhibitor interactions with the protein kinase P-loop.The target discovery process.Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as Potent Dual B-RafV600E/KDR Inhibitors Using Docking and 3D-QSAR Approaches.Marine pyrrolocarbazoles and analogues: synthesis and kinase inhibition.Innovative computer-aided methods for the discovery of new kinase ligands.The induction of CXCR4 expression in human osteoblast-like cells (MG63) by CoCr particles is regulated by the PLC-DAG-PKC pathway.Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors.The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design.Recent advances in retroviruses via cryo-electron microscopy.Current chemical biology tools for studying protein phosphorylation and dephosphorylation.Application of shape-based and pharmacophore-based in silico screens for identification of Type II protein kinase inhibitors.Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis
P2860
Q24647566-71A8FDE3-FF8C-41FE-9A25-1E1C321A5EEEQ27008204-EC0AACE7-11C4-4994-B508-208E6C43D4D9Q27653589-B6FE5D2A-08F9-4F3F-91EE-BFA10E64E509Q27657380-BD21F77D-0660-4873-91BE-16BFE9501090Q27673685-5C580F1F-E569-4CC5-9EE3-BE77B8844E04Q27674646-2F52563E-6F20-42F6-A74A-9AF87613C521Q27682624-D9E3154E-B8EF-40CC-AA58-68EB512DE7CEQ30799661-7FD9B211-10D8-48FA-AA09-039D794B9C5BQ33738369-1D57C9C9-4333-422F-9426-6FC68E1B3EA2Q33798766-B88FE9D1-3A6B-46F0-BAA7-3502B3453D7BQ34608978-49DA5A1B-8C62-43D8-B765-7B13CD21C325Q34810356-5A93E7E6-C95F-484A-94D1-805B6C57F9ACQ35080674-9A4F8F3D-DBFF-4C96-AE65-27BAC8A3117DQ35116085-FEF0FF00-8903-49F3-BF8A-B918B836A026Q35207622-EBA836F0-DB90-4824-B123-ED5F356EAF65Q35606325-ADE7E003-1615-4E22-831E-1B153EE48431Q36059506-9C012877-E624-4656-8231-75BE50952165Q36247419-AA7FD4A9-0980-4953-8A94-E681EDD306B6Q37680686-CB9C5109-3B58-4C15-80A4-8EEAB408FB83Q38814898-F3C1EF45-6CE3-4F45-85A9-EE00523343B1Q39508591-EBC5D065-41A9-48D6-8A39-0A39B4CCFAD5Q40509516-E3D4DBD6-9040-435F-8F4A-E207B4CEF3ACQ47345749-49AC7A17-9F3F-4BE5-8EB5-3DCBA279E8C2Q50355158-22E5C82E-2225-418E-A864-7289A8757C42Q54543704-85DBD193-71F5-42F0-B668-8103977F3688Q54580789-A00AA07C-AD71-4635-809F-5D3A2C994766Q58199705-51744CFC-92CA-40EF-8FB3-F5F6D75E53B7
P2860
Structural biology in drug design: selective protein kinase inhibitors.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Structural biology in drug design: selective protein kinase inhibitors.
@ast
Structural biology in drug design: selective protein kinase inhibitors.
@en
Structural biology in drug design: selective protein kinase inhibitors.
@nl
type
label
Structural biology in drug design: selective protein kinase inhibitors.
@ast
Structural biology in drug design: selective protein kinase inhibitors.
@en
Structural biology in drug design: selective protein kinase inhibitors.
@nl
prefLabel
Structural biology in drug design: selective protein kinase inhibitors.
@ast
Structural biology in drug design: selective protein kinase inhibitors.
@en
Structural biology in drug design: selective protein kinase inhibitors.
@nl
P1433
P1476
Structural biology in drug design: selective protein kinase inhibitors.
@en
P2093
Giovanna Scapin
P304
P356
10.1016/S1359-6446(02)02290-0
P577
2002-06-01T00:00:00Z